XM does not provide services to residents of the United States of America.
R
R

Roche

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Swiss trade surplus at CHF 8.063 bln in October

TABLE-Swiss trade surplus at CHF 8.063 bln in October November 19 (Reuters) - Switzerland ran a merchandise trade surplus of 8 .063 billion Swiss francs in October, the Federal Customs Office said on Tuesday. KEY FIGURES (millions of Swiss francs) October 2024 September 2024 Imports 19.681 17.620 Exports 27.745 22.562 Balance 8.063 4.942 The figures exclude precious metals and stones, works of art and antiques.
C
L
N
R
R
S

Japan's Nikkei tracks Wall Street losses; BOJ coy on hike timing

Japan's Nikkei tracks Wall Street losses; BOJ coy on hike timing Updates with closing prices By Kevin Buckland TOKYO, Nov 18 (Reuters) - Japan's Nikkei share average fell on Monday, taking cues from losses on Wall Street at the end of last week, after Bank of Japan chief Kazuo Ueda failed to offer strong hints on the timing of additional interest rate hikes.
N
R
U
J

Japan's Nikkei falls as tech shares track Wall Street losses

Japan's Nikkei falls as tech shares track Wall Street losses By Kevin Buckland TOKYO, Nov 18 (Reuters) - Japan's Nikkei share average fell on Monday as technology shares tracked U.S peers' losses at the end of last week, while drugmaker shares declined after a noted vaccine sceptic was appointed to head the U.S. Department of Health. Automaker shares came under pressure from an overall stronger yen, although the currency pulled back slightly from early highs after Bank of Japan Governor Kazuo Ue
N
R
U
J

Drugmaker stocks slide as Trump taps vaccine skeptic RFK Jr for US health job

UPDATE 7-Drugmaker stocks slide as Trump taps vaccine skeptic RFK Jr for US health job Vaccine skepticism concerns impact biotech investor sentiment Shares of European drug makers fall, along with U.S. companies Analysts worry about RFK Jr.'s influence on HHS agencies Updates throughout with detail on stock moves By Samuel Indyk and Ludwig Burger Nov 15 (Reuters) - Shares of major U.S.
A
G
M
P
P
R
S
C
K
C

European pharma stocks slip after Trump taps RFK Jr to lead top US health agency

BUZZ-European pharma stocks slip after Trump taps RFK Jr to lead top US health agency ** Share in healthcare companies drop the most in Europe, hurt by the news that Donald Trump has selected Robert F. Kennedy Jr. , who has previously spread misinformation on vaccines, to lead the country's top health agency ** STOXX 600 Healthcare index .SXDP at -2.09% is the biggest faller among the pan-European indices ** At 1113.76 points, the sub-index is at its lowest in 7 months and is heading for its big
A
G
R
S
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.